Skip to main content

Table 1 Demographic and baseline clinical characteristics of patients

From: Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study

 

UFH (n = 20)

UFH + tirofiban (n = 20)

P value

Demographic data

   

   Age in years, median (range)

71 (44, 85)

70 (52, 81)

0.932

   Female/male, number

8/12

9/11

0.757

Severity of illness scores

   

   APACHE II score, median (range)

27 (18, 34)

28 (18, 34)

0.523

   SAPS II, median (range)

46 (31, 66)

48 (30, 64)

0.768

Cardiogenic shock: reasons and haemodynamics at admission

   

   Acute coronary syndromes, number

17

19

0.304

   Acute decompensation of CHF, number

3

1

0.304

   Left ventricular ejection fraction as a percentage, median (range)

31 (20, 57)

30 (18, 54)

0.446

   Cardiac index in L/minute per square metre, median (range)

2 (1.4, 2.4)

2 (1.6, 2.4)

0.955

Renal failure: reasons and parameters at admission

   

   Acute kidney injury, number

16

17

0.688

   Acute decompensation of CRI, number

4

3

0.688

   Creatinine in mg/dL, mean ± SD

2.9 ± 0.3

2.5 ± 0.2

0.788

   Blood urea nitrogen in mg/dL, mean ± SD

72 ± 23.3

70 ± 24.1

0.734

Haematology

   

   Platelet count, × 109/L, mean ± SD

216 ± 64.3

194 ± 39.5

0.212

   Monocyte count, × 106/L, mean ± SD

1,059 ± 85.4

981 ± 103

0.561

   Platelet-monocyte aggregates as a percentage, mean ± SD

20.2 ± 5.9

20.8 ± 6.1

0.751

  1. APACHE, Acute Physiology and Chronic Health Evaluation; CHF, chronic heart failure; CRI, chronic renal insufficiency; SAPS, Simplified Acute Physiology Score; SD, standard deviation; UFH, unfractioned heparin.